Lokken Investment Group LLC Has $3.12 Million Stock Holdings in Eli Lilly and Company $LLY

Lokken Investment Group LLC decreased its stake in Eli Lilly and Company (NYSE:LLY) by 24.5% in the third quarter, HoldingsChannel reports. The firm owned 4,090 shares of the company’s stock after selling 1,329 shares during the period. Eli Lilly and Company accounts for 1.1% of Lokken Investment Group LLC’s holdings, making the stock its 24th biggest position. Lokken Investment Group LLC’s holdings in Eli Lilly and Company were worth $3,121,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Bank of Marin raised its holdings in Eli Lilly and Company by 2.3% during the 3rd quarter. Bank of Marin now owns 1,573 shares of the company’s stock worth $1,200,000 after buying an additional 35 shares during the period. Pinnacle West Asset Management Inc. increased its position in shares of Eli Lilly and Company by 0.3% in the third quarter. Pinnacle West Asset Management Inc. now owns 4,421 shares of the company’s stock worth $3,373,000 after acquiring an additional 13 shares in the last quarter. Ashton Thomas Private Wealth LLC raised its holdings in shares of Eli Lilly and Company by 15.8% during the third quarter. Ashton Thomas Private Wealth LLC now owns 21,245 shares of the company’s stock valued at $16,210,000 after acquiring an additional 2,901 shares during the period. Valley Brook Capital Group Inc. raised its holdings in shares of Eli Lilly and Company by 5.3% during the third quarter. Valley Brook Capital Group Inc. now owns 1,687 shares of the company’s stock valued at $1,287,000 after acquiring an additional 85 shares during the period. Finally, Premier Path Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 1.8% in the 3rd quarter. Premier Path Wealth Partners LLC now owns 6,174 shares of the company’s stock valued at $4,711,000 after acquiring an additional 107 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 3.9%

NYSE:LLY opened at $1,003.21 on Wednesday. The company has a market capitalization of $948.41 billion, a P/E ratio of 49.08, a P/E/G ratio of 0.79 and a beta of 0.39. The stock’s 50 day moving average price is $1,054.28 and its 200 day moving average price is $893.81. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 29.35%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. National Bankshares set a $1,286.00 target price on shares of Eli Lilly and Company in a research note on Monday, December 1st. Truist Financial upped their price target on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Guggenheim decreased their price objective on Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Morgan Stanley raised their price target on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,162.75.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Agreed to acquire Seamless Therapeutics assets in a ~$1.12B deal to enter the hearing‑loss/gene‑editing space, diversifying beyond weight‑loss drugs and adding a high‑potential biologics/genetic therapy program. Eli Lilly Is Getting Into the Hearing Loss Market in a $1.12 Billion Deal With Seamless Therapeutics
• Positive Sentiment: Entered a global R&D collaboration and license with Zonsen PepLib Biotech — expands Lilly’s discovery capabilities and early‑stage pipeline exposure. Zonsen PepLib Biotech Enters Global R&D Collaboration and License Agreement with Lilly
• Positive Sentiment: Plans a $3.5B injectable manufacturing campus in Pennsylvania to increase capacity for biologics/GLP‑1 injectables — supports supply for Mounjaro/Zepbound and future injectable launches. Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
• Positive Sentiment: Set to buy ~5% of Veradermics in its IPO — a small strategic stake that gives Lilly exposure to hair‑loss therapeutics and expands external innovation pipeline touchpoints. Eli Lilly (LLY) to Buy 5% of Veradermics Stock in IPO
• Positive Sentiment: Ventyx Biosciences shareholder vote set for March on Lilly’s $14/share cash merger — progress on acquisitions that can add targeted assets. Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger
• Neutral Sentiment: Formed a strategic collaboration with Repertoire Immune Medicines — increases discovery partnerships but impact timing/value is uncertain. Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines
• Neutral Sentiment: Analysts expect a revenue beat for Q4 driven by GLP‑1 sales, though EPS could be pressured; investors are watching tomorrow’s results for confirmation. Eli Lilly Expected to Report Higher 4Q Profit, Revenue — Earnings Preview
• Neutral Sentiment: Media/TV commentary (e.g., Jim Cramer) suggests upcoming data releases could move the stock — speculative near‑term catalyst. Jim Cramer says Eli Lilly could announce some new data, and that could get the stock rolling
• Negative Sentiment: Competitive pressure and falling U.S. prices for GLP‑1 obesity drugs (Novo and others) are tightening addressable market forecasts and could slow revenue growth/pricing power. Obesity market sales potential tightens as Novo and Lilly enter new era
• Negative Sentiment: Wall Street notes rising R&D and manufacturing costs (expansion and pipeline investing) that could weigh on near‑term margins and EPS despite strong revenue. Eli Lilly Q4 Preview: Wall St Sees Revenue Beat On Weight-Loss Heft But R&D Costs Could Drag Profits

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.